Summary:
- This article discusses the upcoming availability of a new injectable HIV prevention medication called cabotegravir, which only needs to be administered every 6 months.
- The article highlights the potential challenges South Africa may face in tracking and managing the distribution of this new medication to millions of people who could benefit from it.
- The article also discusses the importance of this new medication in helping to reduce the burden of HIV/AIDS in South Africa, which has one of the highest HIV prevalence rates in the world.